Avera is a specialty pharmaceutical company focused on the acquisition, development and commercialization of novel pharmaceutical compounds. To date, Avera has built a strong pipeline by acquiring high-value assets from Novartis AG, Eli Lilly & Co., and GlaxoSmithKline. Through in-licensing, Avera will continue to build its pipeline of novel, clinical-stage assets that address areas of significant unmet medical need. Avera’s greatest strength and expertise is in drug development. Currently, the company is developing a pipeline of drug candidates to treat Irritable Bowel Syndrome, Overactive Bladder, Cognitive Impairment Associated with Schizophrenia, and Dementia, as well as a neuromuscular blocking agent for both rapid and routine endotracheal intubation and skeletal muscle relaxation during surgery.

Avera Pharmaceuticals licenses from Cornell University a Proprietary Surgical Muscle Relaxant and Reversal Agent Compound for the Anesthesia Market March 21, 2007 More News >>

 

Home | Company Profile | Strategy | Therapeutic Interests | Product Pipeline | Business Development | Contact Us

© 2002-2006 Avera Pharmaceuticals, Inc.